曲昔多巴治疗进行性核上性麻痹步态障碍一例

Effect of droxidopa on the gait disorder in an patient with progressive supranuclear palsy

目的探讨曲昔多巴在治疗进行性核上性麻痹患者步态障碍中的疗效。方法给1例进行性核上性麻痹患者加用曲昔多巴,在治疗期间观察其对步态障碍的改善情况,并监测血压的变化。结果曲昔多巴治疗量达200mg.d-1,患者自感头晕好转,但步态障碍改善不明显,加量至300mg.d-1,患者步态障碍改善仍不明显,但血压升高。结论用曲昔多巴治疗进行性核上性麻痹患者步态障碍疗效欠佳,且药物使用应从低剂量开始,谨慎增至维持剂量,密切观察患者血压变化。

Objective To observe the clinical effect of droxidopa on the gait disorder in a patient with progressive supranuclear palsy( PSP).Methods A patient with PSP was managed with titratable droxidopa. During the treatment,the symptoms of gait disorder were observed,and blood pressure was monitored. Results When droxidopa dose amounted to 200 mg · d-1,the patient 's dizziness got better,but no obvious improvement in gait disorder.When the dose up to 300mg·d-1,gait disorder improvement was not still observed,but blood pressure was elevated.Conclusion The effects of droxidopa on gait disorder in patients with PSP is not clear. It should be titratably used to up to maintenance dose with caution,while the patient's blood pressure should be monitored.